Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
Nasopharyngeal carcinoma: an evolving paradigm
The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Tumor cells form immune escape and subsequently obtain unlimited proliferation ability due
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
[HTML][HTML] EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1
J Wang, J Ge, Y Wang, F Xiong, J Guo, X Jiang… - Nature …, 2022 - nature.com
Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely
related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric …
related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric …
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
W Fang, Y Yang, Y Ma, S Hong, L Lin, X He… - The Lancet …, 2018 - thelancet.com
Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …
plus cisplatin, are generally considered the first-line standard of care for patients with …
[HTML][HTML] Molecular and biochemical aspects of the PD-1 checkpoint pathway
VA Boussiotis - New England Journal of Medicine, 2016 - Mass Medical Soc
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
[HTML][HTML] Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 …
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An
International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) - PMC Back …
International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) - PMC Back …
PD‐1/PD‐L1 immune checkpoint: potential target for cancer therapy
Recent studies show that cancer cells are sometimes able to evade the host immunity in the
tumor microenvironment. Cancer cells can express high levels of immune inhibitory …
tumor microenvironment. Cancer cells can express high levels of immune inhibitory …
Nasopharyngeal carcinoma
Epidemiological trends during the past decade suggest that although incidence of
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …
[HTML][HTML] Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …
attack from immune cells. Cancer cells can express many immune inhibitory signalling …